Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia

Leukemia

Volumn 28, Issue 1, 2014, Pages 179-182

  Martins, L R ^a   Lucio P ^b   Melao A ^a   Antunes, I ^a   Cardoso, B A ^a   Stansfield, R ^c   Bertilaccio, M T S ^d   Ghia, P ^d,e   Drygin, D ^c   Silva, M G ^b   Barata, J T ^a  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b NOVA MEDICAL SCHOOL   (Portugal)

^c Cylene Pharmaceuticals   (United States)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CX 4945; FLUDARABINE; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; CANCER CELL; CHRONIC LYMPHATIC LEUKEMIA; COCULTURE; DRUG CYTOTOXICITY; ENZYME ACTIVITY; HIGH RISK POPULATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LETTER; LYMPHOCYTE; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NAPHTHYRIDINES;

EID: 84891855786     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.232     Document Type: Letter

References (15)

1. Gribben JG, O'Brien S. Update on therapy of chronic lymphocytic leukemia. J Clin Oncol 2011; 29: 544-550.
2. Faderl S, Ferrajoli A, Frankfurt O, Pettitt A. Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy. Leukemia 2009; 23: 457-466.
3. Piazza F, Manni S, Ruzzene M, Pinna LA, Gurrieri C, Semenzato G. Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways. Leukemia 2012; 26: 1174-1179.
4. Martins LR, Lucio P, Silva MC, Anderes KL, Gameiro P, Silva MG et al. Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia. Blood 2010; 116: 2724-2731.
5. Shehata M, Schnabl S, Demirtas D, Hilgarth M, Hubmann R, Ponath E et al. Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia. Blood 2010; 116: 2513-2521.
6. Cuni S, Perez-Aciego P, Perez-Chacon G, Vargas JA, Sanchez A, Martin-Saavedra FM et al. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 2004; 18: 1391-1400. (Pubitemid 39136749)
7. Barata JT. The impact of PTEN regulation by CK2 on PI3K-dependent signaling and leukemia cell survival. Adv Enzyme Regul 2011; 51: 37-49.
8. Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, O'Brien SE et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res 2010; 70: 10288-10298.
9. Marschke R, Borad M, McFarland R, Alvarez R, Lim J, Padgett C et al. Findings from the Phase I clinical trials of CX-4945, an orally bioavailable inhibitor of CK2. J Clin Oncol 2011; 29(Suppl): abstract 3087.
10. Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, Brustolon F et al. Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ 2005; 12: 668-677. (Pubitemid 40767169)
11. Ringshausen I, Oelsner M, Weick K, Bogner C, Peschel C, Decker T. Mechanisms of apoptosis-induction by rottlerin: therapeutic implications for B-CLL. Leukemia 2006; 20: 514-520. (Pubitemid 43291752)
12. Longo PG, Laurenti L, Gobessi S, Petlickovski A, Pelosi M, Chiusolo P et al. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia 2007; 21: 110-120. (Pubitemid 44921842)
13. el Rouby S, Thomas A, Costin D, Rosenberg CR, Potmesil M, Silber R et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993; 82: 3452-3459. (Pubitemid 23356719)
14. Dohner H, Stilgenbauer S, James MR, Benner A, Weilguni T, Bentz M et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997; 89: 2516-2522. (Pubitemid 27143300)
15. Tsimberidou AM, Keating MJ. Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options. Leuk Lymphoma 2010; 51: 1188-1199.